BC Extra | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

Black Diamond raises $201M in public debut  Black Diamond Therapeutics Inc. (NASDAQ:BDTX) raised $201.1 million late Wednesday through the sale of 10.6 million shares at $19 in a bumped-up IPO, valuing the company at $652.1...
BC Extra | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
BC Extra | Mar 21, 2019
Clinical News

Conatus sinks after NASH therapy misses fibrosis endpoint

Conatus lost $1.49 (51%) to $1.42 in after-hours trading Thursday after reporting that emricasan missed the primary endpoint in the Phase IIb ENCORE-NF to treat non-alcoholic steatohepatitis fibrosis. ENCORE-NF's primary endpoint evaluated the proportion of...
BC Week In Review | Dec 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb for NASH cirrhosis

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week 24 vs. placebo in the Phase IIb ENCORE-PH trial...
BC Extra | Dec 6, 2018
Clinical News

Conatus down on Phase IIb NASH miss

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) lost $2.56 (57%) to $1.94 on Thursday after it said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week...
BC Week In Review | Nov 2, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
BC Extra | Oct 29, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
BC Week In Review | Apr 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb in liver transplant patients

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said emricasan missed the primary endpoint of improving fibrosis in the Phase IIb POLT-HCV-SVR trial in post-orthotopic liver transplant recipients with fibrosis or cirrhosis. The trial enrolled 51 patients whose transplanted...
BC Extra | Apr 5, 2018
Clinical News

Conatus falls as emricasan misses in liver transplant patients

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) fell $1.89 (31%) to $4.12 on Thursday after reporting that emricasan missed the primary endpoint of improving fibrosis in the Phase IIb POLT-HCV-SVR trial in post-orthotopic liver transplant recipients with fibrosis...
BioCentury | Sep 16, 2017
Strategy

Passing the baton

When he takes the helm as CEO of Novartis AG in January, Vasant Narasimhan will inherit a business that is still struggling to plug the revenue hole from cancer drug Gleevec imatinib going off patent...
Items per page:
1 - 10 of 92
BC Extra | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

Black Diamond raises $201M in public debut  Black Diamond Therapeutics Inc. (NASDAQ:BDTX) raised $201.1 million late Wednesday through the sale of 10.6 million shares at $19 in a bumped-up IPO, valuing the company at $652.1...
BC Extra | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
BC Extra | Mar 21, 2019
Clinical News

Conatus sinks after NASH therapy misses fibrosis endpoint

Conatus lost $1.49 (51%) to $1.42 in after-hours trading Thursday after reporting that emricasan missed the primary endpoint in the Phase IIb ENCORE-NF to treat non-alcoholic steatohepatitis fibrosis. ENCORE-NF's primary endpoint evaluated the proportion of...
BC Week In Review | Dec 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb for NASH cirrhosis

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week 24 vs. placebo in the Phase IIb ENCORE-PH trial...
BC Extra | Dec 6, 2018
Clinical News

Conatus down on Phase IIb NASH miss

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) lost $2.56 (57%) to $1.94 on Thursday after it said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week...
BC Week In Review | Nov 2, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
BC Extra | Oct 29, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
BC Week In Review | Apr 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb in liver transplant patients

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said emricasan missed the primary endpoint of improving fibrosis in the Phase IIb POLT-HCV-SVR trial in post-orthotopic liver transplant recipients with fibrosis or cirrhosis. The trial enrolled 51 patients whose transplanted...
BC Extra | Apr 5, 2018
Clinical News

Conatus falls as emricasan misses in liver transplant patients

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) fell $1.89 (31%) to $4.12 on Thursday after reporting that emricasan missed the primary endpoint of improving fibrosis in the Phase IIb POLT-HCV-SVR trial in post-orthotopic liver transplant recipients with fibrosis...
BioCentury | Sep 16, 2017
Strategy

Passing the baton

When he takes the helm as CEO of Novartis AG in January, Vasant Narasimhan will inherit a business that is still struggling to plug the revenue hole from cancer drug Gleevec imatinib going off patent...
Items per page:
1 - 10 of 92